Text Size
24 studies found for:    Open Studies | "Sarcoma, Kaposi"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
2 Recruiting Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   Recurrent Kaposi Sarcoma
Interventions: Drug: lenalidomide;   Other: laboratory biomarker analysis
3 Recruiting Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Condition: Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
4 Recruiting Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: bortezomib;   Other: laboratory biomarker analysis
5 Unknown † Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
Condition: Kaposi's Sarcoma
Intervention: Drug: Indinavir in association with Vinblastina +/- Bleomicina
6 Recruiting Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
Condition: Kaposi's Sarcoma
Intervention:
7 Unknown † Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Condition: Kaposi´s Sarcoma
Intervention: Drug: Bevacizumab
8 Recruiting A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
9 Not yet recruiting Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe
Conditions: Kaposi Sarcoma (KS);   HIV
Intervention: Other: KS structured clinical care training
10 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus;   Other: laboratory biomarker analysis;   Biological: DEC-205-NY-ESO-1 fusion protein vaccine
11 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
Conditions: HIV-1 Infection;   Kaposi's Sarcoma
Interventions: Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate;   Drug: etoposide
13 Recruiting Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Conditions: HIV Infection;   Kaposi's Sarcoma
Intervention:
14 Recruiting 124I-FIAU Imaging in EBV and KSHV Associated Cancers
Conditions: Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Kaposi's Sarcoma;   Gastric Cancer;   Nasopharyngeal Cancer
Interventions: Other: FIAU-PET-CT scans;   Other: FIAU-PET-CT scan
15 Recruiting Spectroscopy With Surface Coils and Decoupling
Conditions: Adrenal Cortical Cancer;   Brain Cancer;   Breast Cancer;   CNS Cancer;   Colon Cancer;   HEENT Cancer;   Hodgkin's Disease;   Kaposi's Sarcoma;   Liver Cancer;   Lung Cancer;   Non-Hodgkin's Lymphoma;   Ovarian Cancer;   Pancreatic Cancer;   Prostate Cancer;   Rectal Cancer;   Renal Cancer;   Sarcoma;   Squamous Cell Carcinoma;   Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T;   Device: 1H Spectroscopy at 1.5T and 3T
16 Recruiting History of the KSHV Inflammatory Cytokine Syndrome (KICS)
Conditions: KSHV Inflammatory Cytokine Syndrome (KICS);   KSHV;   HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir;   Drug: Rituximab/Liposoma Doxorubicin
17 Recruiting Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Conditions: Castleman Disease;   Castleman's Disease;   Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine;   Drug: Tocilizumab;   Drug: Valganciclovir
18 Recruiting Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
19 Unknown † Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
20 Unknown † Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
Condition: Cancer
Interventions: Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: assessment of therapy complications;   Procedure: fertility assessment and management;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
To Top

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
† Indicates status has not been verified in more than two years